TABLE 1.
Characteristics of patients
| Characteristics | N (%) |
|---|---|
| Total | 111 (100) |
| Gender | |
| Male | 64 (57.7) |
| Female | 47 (42.3) |
| Age | |
| Median (range), y | 49 (14‐85) |
| Histopathology | |
| ACC | 39 (35.1) |
| Sarcoma | 23 (20.7) |
| SCC | 19 (17.1) |
| Melanoma | 11 (9.9) |
| ONB | 9 (8.1) |
| Adenocarcinoma | 3 (2.7) |
| Myoepithelial carcinoma | 2 (1.8) |
| Mucoepidermoid carcinoma | 1 (0.9) |
| Poor‐differentiated carcinoma | 1 (0.9) |
| Neuroendocrine carcinoma | 1 (0.9) |
| Salivary origin malignancy | 1 (0.9) |
| SMARCB1 (INI‐1)‐deficient carcinoma | 1 (0.9) |
| Radiation‐induced second primary malignancies | |
| Yes | 4 (3.6) |
| No | 107 (96.4) |
| T category | |
| T1 | 7 (6.3) |
| T2 | 9 (8.1) |
| T3 | 18 (16.2) |
| T4 | 77 (69.4) |
| N category | |
| N0 | 100 (90.1) |
| N1‐3 | 11 (9.9) |
| Surgery | |
| Without surgery | 9 (8.1) |
| With surgery | 72 (64.9) |
| Biopsy | 30 (27.0) |
| Surgical margin* | |
| R1/R0 | 19 (17.1) |
| R2/Biopsy | 92 (82.9) |
| Gross tumor | |
| With gross tumor | 92 (82.9) |
| Without gross tumor | 19 (17.1) |
| GTV ml, median (range) | 51 (0‐225.6) |
| Tumor status | |
| Primary | 76 (68.5) |
| Recurrence | 35 (31.5) |
| Re‐irradiation | |
| Yes | 30 (27.0) |
| No | 81 (73.0) |
| PRT dose | |
| 56 Gy (RBE)/28 frs. | 2 (1.8) |
| 66 Gy (RBE)/33 frs. | 1 (0.9) |
| 70 Gy (RBE)/35 frs. | 1 (0.9) |
| CIRT dose | |
| 60 Gy (RBE)/20 frs. | 4 (3.6) |
| 63 Gy (RBE)/18 frs. | 22 (19.8) |
| 63 Gy (RBE)/21 frs. | 26 (23.4) |
| 66 Gy (RBE)/22 frs. | 6 (5.4) |
| 70 Gy (RBE)/20 frs. | 10 (9.0) |
| 73.5 Gy (RBE)/21 frs. | 2 (1.8) |
| PRT + CIRT dose | |
| 69 Gy (RBE)/32 frs. | 2 (1.8) |
| 71 Gy (RBE)/33 frs. | 24 (21.6) |
| 73.5 Gy (RBE)/33 frs. | 11 (9.9) |
| Radiation technique | |
| PRT | 4 (3.6) |
| CIRT | 70 (63.1) |
| PRT and CIRT | 37 (33.3) |
| Concurrent chemotherapy | |
| Yes | 19 (17.1) |
| No | 92 (82.9) |
Abbreviations: ACC, adenoid cystic carcinoma; CIRT, carbon‐ion radiotherapy; ONB, olfactory neuroblastoma; PRT, proton radiotherapy; SCC, squamous cell carcinoma.
*
Surgical margin was not reported for some of the patients. Those patients were grouped to R1/R0 or R2/biopsy according to MRI findings.